Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.23 -0.67%

-$0.09 today

Market cap
$239.70M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.81M

Average 0.17M

ENTA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Enanta Pharmaceuticals, Inc.NASDAQ: ENTA

Stock-Based Compensation · Q2 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $3.75M fell 20.1% year over year, ahead of the -32.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Stock-based compensation amounted to 28.4% of revenue in FY2025, down 11.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.1% holds above the trailing-twelve-month pace of -32.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.75M-1.6% QoQ
Last fiscal yearSep 2025
$18.57M-30.7% YoY
LTMMar 2026
$15.77M-32.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.1%——
1 year-30.7%——
3-year CAGR-11.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
18.57M USD
Year-over-year change
-30.7%
4-year CAGR
-3.0%

Stock-Based Compensation vs competitors

How ENTA compares with its peers on the latest reported figures

  • ENTA's LTM Mar 2026 stock-based compensation of $15.77M is the 2nd largest of the 11 companies compared; the peer median is $9.13M.
  • Its year-over-year change of -32.9% is the 6th highest of 11, against a peer median of -33.1%.
  • Stock-based compensation amounts to 22.8% of revenue for ENTA, versus a peer median of 59.0%.
ENTA Competitors Peer median
Stock-Based Compensation for ENTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M -62.1%-23.7%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M -32.9%-11.7%22.8%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$13.6M -8.6%+16.5%37.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M -28.1%+4.4%5116.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M -60.8%-22.0%60.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026$8.17M -33.3%-9.2%59.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.04M -48.6%-13.0%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$5.08M +64.3%-10.8%7.1%
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding ENTA) $9.13M-33.1%-10.0%59.0%

Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(79M)(121.76M)(133.82M)(116.05M)(81.89M)
Depreciation & Amortization3.33M2.97M2.37M2.34M5.09M
Deferred Income Tax345K0000
Stock-Based Compensation20.99M26.97M28.22M26.8M18.57M
Change in Working Capital(13.69M)6.79M8.02M7.13M39.91M
Accounts Receivables(24.3M)11.8M9.42M973K31.76M
Inventory00000
Accounts Payables3.77M(4.63M)(1.15M)(414K)(1.31M)
Other Working Capital6.84M(372K)(243K)6.57M9.46M
Other Non-Cash Items(1.98M)242K(7.95M)1.02M(946K)
Operating Cash Flow(70M)(84.78M)(103.15M)(78.76M)(19.27M)
Capital Expenditures(750K)(2.13M)(9.06M)(17.95M)(12.9M)
Acquisitions (Net)(37.74M)(54.9M)44.52M00
Purchases of Investments(307.35M)(171.45M)(373.39M)(307.28M)(209.63M)
Sales of Investments345.09M228.47M328.87M383.47M262.87M
Other Investing Activities37.74M54.9M(44.52M)00
Investing Cash Flow36.99M54.9M(53.58M)58.24M40.35M
Debt Repayment00199.68M(27.48M)(26.49M)
Common Stock Issued3.61M21.26M2.21M147K145K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(534K)(1.23M)(3.76M)(294K)(277K)
Financing Cash Flow3.08M20.03M198.13M(27.63M)(26.62M)
Effect of Forex Changes00000
Net Change in Cash(29.93M)(9.85M)41.39M(48.16M)(5.54M)
Free Cash Flow(70.75M)(86.91M)(112.21M)(96.71M)(32.17M)

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Intrinsic Alpha fair value

Locked

Current Price

$8.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.